On the other hand, Nivolumab, a human IgG4 Programmed Death‐1 (PD‐1) immune checkpoint inhibitor, disrupts Programmed Death‐Ligand 1 (PD‐L1) mediated signaling to provide anti‐tumor therapy [8]. This evidence concerns the gene CD274 and neoplasm.